Jonathan Appleby, currently an executive at the rare disease unit of GlaxoSmithKline Plc, will join the UK Cell and Gene Therapy Catapult on 1 October as chief scientific officer. The Catapult provides development and manufacturing services to companies developing cell and gene therapies. Dr Appleby holds a PhD from the department of biochemistry and molecular biology at the University of Leeds, UK. At GSK’s rare diseases unit, he was medicines development leader for Strimvelis, a gene therapy approved in Europe for the treatment of ADA-SCID.
The Cell and Gene Therapy Catapult announced the appointment on 6 June 2018.
Copyright 2018 Evernow Publishing Ltd